BioStock: Ultimovacs presents INITIUM study design at AACR

The American Association for Cancer Research kicked off its annual meeting last week to put the top ongoing cancer clinical trials front and centre. Norwegian Ultimovacs attended the virtual conference and presented a poster explaining the trial design of their INITIUM study, one of two ongoing proof-of-concept trials testing their universal cancer vaccine UV1.

Read the full article at biostock.se:

https://www.biostock.se/en/ultimovacs-presents-initium-study-design-at-aacr/

This is a press release from BioStock - Connecting Innovation & Capital.